Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.

ABSTRACT:

Background

Although influenza vaccination has been shown to reduce the incidence of major adverse cardiac events (MACE) among those with existing cardiovascular disease (CVD), in the 2015-16 season, coverage for persons with heart disease was only 48% in the US.

Methods

We built a Monte Carlo (probabilistic) spreadsheet-based decision tree in 2018 to estimate the cost-effectiveness of increased influenza vaccination to prevent MACE readmissions. We based our model on current US influenza vaccination coverage of the estimated 493,750 US acute coronary syndrome (ACS) patients from the healthcare payer perspective. We excluded outpatient costs and time lost from work and included only hospitalization and vaccination costs. We also estimated the incremental cost/MACE case averte

SUBMITTER: Peasah SK 

PROVIDER: S-EPMC6488048 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature